Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Febuxostat (Primary) ; Verinurad (Primary)
Indications Hyperuricaemia; Proteinuria; Type 2 diabetes mellitus
Focus Proof of concept; Therapeutic Use
Acronyms CITRINE
Sponsors AstraZeneca

Most Recent Events

01 Apr 2021 Primary endpoint (Urinary Albumin to Creatinine Ratio (UACR)) has been met.
01 Apr 2021 Primary endpoint (Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo) has been met.
01 Apr 2021 Results published in the American Journal of Kidney Diseases.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight